[ET Net News Agency, 13 November 2019] Jacobson Pharma Corporation Limited (02633) said
the group is expected to record an increase of over 30% in the consolidated profit
attributable to shareholders of the company for the six months ended 30 September 2019 as
compared to that for the six months ended 30 September 2018.
The expected increase is mainly attributable to the steady growth of the group's generic
drug business augmented with the sales revenue generated from newly in-licensed products,
in addition to an uplifted sales performance on proprietary medicines. Operating leverage
and financial savings derived from cost control measures also helped contribute to the
expected increase in earnings. Fair value gain on redemption of convertible notes and
investment properties of the group is also expected to contribute, although to a lesser
extent, to the increase in consolidated profit attributable to shareholders of the
company. (RC)
|
|
|
|
|
|
|
|
|
|
Super Quote | Detail Quote | Interactive Chart | Transaction | Related News | Related Securities | Company Information | Dividend Records | Short Sell
02633 JACOBSON PHARMA
Nominal 
0.570 0.000 (0.000%) Others
13/11/2019 17:24
Jacobson Pharma (02633) sees 30+% increase in interim net
| Remark: | Real time quote last updated: 25/04/2024 17:52 |
| Real-time basic market prices of Hong Kong securities are provided by HKEx; a Designated Website authorized by the HKEx Group to provide the Service |